Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602908 | 0.73 | NOTUM (0.42) | NPC1LMNATSHRMAPK1SCN4A | |
| SCHEMBL16719919 | 0.67 | ALDH1A1 (0.31) | — | |
| SCHEMBL6071730 | 0.67 | KDM4E (0.41) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL21598393 | 0.65 | TNKS (0.37) | PARP1 | |
| SCHEMBL25392290 | 0.65 | NOTUM (0.56) | — | |
| SCHEMBL7983360 | 0.63 | PRCP (0.31) | PARP1 | |
| SCHEMBL6072537 | 0.63 | NOTUM (0.40) | — | |
| SCHEMBL11570230 | 0.61 | NPC1 (0.54) | NPC1MAPK1 | |
| SCHEMBL1450390 | 0.61 | MTNR1A (0.32) | — | |
| SCHEMBL9587594 | 0.61 | BRPF1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461159-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | Jannsen Pharmaceutica BV (BE) | 2013-06-11 | — | — | US | claimed |
| WO-2010068453-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | claimed |
| US-8877769-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | JANSEEN PHARMACEUTICA NV (BG) | 2014-11-04 | — | — | US | disclosed |
| US-20130245022-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | disclosed |
| US-8461159-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | Jannsen Pharmaceutica BV (BE) | 2013-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245022-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | PARP1 1766/4885NPC1 1573/4885LMNA 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.